Table 1.

Radiosensitization of Human Cancer Cells by UPS Inhibitors.

	Developmental Stages	Radiosensitization Activity	Cancer Types	References
UPS inhibitors
Bortezomib	Clinical use	Yes	Prostate, gastric, cervical, rectal, esophageal, lung, and liver cancers; lymphoma; and central nervous system malignancies	[58–60,64,116–118,129]
Marizomib	Phase 1	Yes	Glioma	[63]
MG-132	Preclinical	Yes	Prostate and lung cancers; Hodgkin's lymphoma; and melanoma	[55,61,62,130,131]
CRL inhibitor
MLN4924	Phase 1	Yes	Pancreatic, lung, and breast cancers	[91,119]